New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Annual Meeting of the American Society of Clinical Oncology (ASCO), this year held in Chicago, Illinois from May 30 to June 2 ...

The outbreak occurred in a flock of 190 backyard poultry birds in the district of Birzgales, Paris-based WOAH said in a notice, citing Latvian authorities. Vera shares skyrocket as kidney disease drug ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

"It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader,” said Jesse Shefferman, Chief Executive ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Merck’s combo of KEYTRUDA and Trodelvy reduces disease progression or death risk by 35% in tough-to-treat breast cancer.

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...